Evidence map›Paper›PMID 30482776›Full record

ArticleCancer research2019

Ribosomal Lesions Promote Oncogenic Mutagenesis.

Sergey O Sulima, Kim R Kampen, Stijn Vereecke, Daniele Pepe, Laura Fancello, Jelle Verbeeck, Jonathan D Dinman, Kim De Keersmaecker

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. RiboScreenBiomedicines · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Ribosome specialization by cancer-associated ribosomal protein mutations: progress made and open questions.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sergey O SulimaDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium.
Kim R KampenDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium.
Stijn VereeckeDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium.ORCID 0000-0001-8414-8907
Daniele PepeDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium.
Laura FancelloDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium.
Jelle VerbeeckDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium.
Jonathan D DinmanDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland.ORCID 0000-0002-2402-9698
Kim De KeersmaeckerDepartment of Oncology, KU Leuven, LKI - Leuven Cancer Institute, Leuven, Belgium. kim.dekeersmaecker@kuleuven.be.ORCID 0000-0002-7420-9531
VIB-KU Leuven Center for Cancer Biology · BEUniversity of Maryland, College Park · US

Funding

X-linked Dyskeratosis Congenita and Ribosomal FrameshiftingR01HL119439 · NHLBI · UNIV OF MARYLAND, COLLEGE PARK · PI DINMAN, JONATHAN D, RUGGERO, DAVIDE · 2014 to 2017
$2.8M
Regulation of programmed -1 ribosomal frameshifting by micro-RNAsR01GM117177 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI DINMAN, JONATHAN D · 2015 to 2018
$1.2M
European Research Council 334946NHLBI NIH HHS R01 HL119439NIGMS NIH HHS R01 GM117177
6 · The paper itself

Abstract

Ribosomopathies are congenital disorders caused by mutations in ribosomal proteins (RP) or assembly factors and are characterized by cellular hypoproliferation at an early stage. Paradoxically, many of these disorders have an elevated risk to progress to hyperproliferative cancer at a later stage. In addition, somatic RP mutations have recently been identified in various cancer types, for example, the recurrent RPL10-R98S mutation in T-cell acute lymphoblastic leukemia (T-ALL) and RPS15 mutations in chronic lymphocytic leukemia (CLL). We previously showed that RPL10-R98S promotes expression of oncogenes, but also induces a proliferative defect due to elevated oxidative stress. In this study, we demonstrate that this proliferation defect is eventually rescued by RPL10-R98S mouse lymphoid cells that acquire 5-fold more secondary mutations than RPL10-WT cells. The presence of RPL10-R98S and other RP mutations also correlated with a higher mutational load in patients with T-ALL, with an enrichment in NOTCH1-activating lesions. RPL10-R98S-associated cellular oxidative stress promoted DNA damage and impaired cell growth. Expression of NOTCH1 eliminated these phenotypes in RPL10-R98S cells, in part via downregulation of PKC-θ, with no effect on RPL10-WT cells. Patients with RP-mutant CLL also demonstrated a higher mutational burden, enriched for mutations that may diminish oxidative stress. We propose that oxidative stress due to ribosome dysfunction causes hypoproliferation and cellular insufficiency in ribosomopathies and RP-mutant cancer. This drives surviving cells, potentiated by genomic instability, to acquire rescuing mutations, which ultimately promote transition to hyperproliferation. SIGNIFICANCE: Ribosomal lesions cause oxidative stress and increase mutagenesis, promoting acquisition of rescuing mutations that stimulate proliferation.

Indexed as

AnimalsCell Line, TumorCell ProliferationHumansMaleMiceMice, TransgenicMutagenesisMutationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaReceptor, Notch1Ribosomal Protein L10Ribosomal ProteinsRibosomesNOTCH1 protein, humanNotch1 protein, mouseReceptor, Notch1Ribosomal ProteinsRPL10 protein, humanRpl10 protein, mouse

Identifiers

PMID30482776
PMCPMC7116100
OpenAlexW2902019779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.